Darrin Uecker - 12 Jun 2023 Form 4/A - Amendment Insider Report for Pulse Biosciences, Inc. (PLSE)

Role: Chief Technology Officer, Director
Signature: /s/ Kenneth B. Stratton, as Attorney-in-Fact
Issuer symbol: PLSE
Transactions as of: 12 Jun 2023
Net transactions value: +$15,098
Form type: 4/A - Amendment
Filing time: 06 Jul 2023, 20:36:07 UTC
Date Of Original Report: 13 Jun 2023
Previous filing: 02 May 2023
Next filing: 14 Jul 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	PLSE	Common Stock	Exercise of in-the-money or at-the-money derivative security	$15,098	+7,365	+5.2%	$2.05	148,941	12 Jun 2023	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	PLSE	Warrant (right to buy)	Exercise of in-the-money or at-the-money derivative security	$0	-7,365	-100%	$0.000000^*	0	12 Jun 2023	Common Stock	7,365	$2.05	Direct

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The number of shares beneficially owned, as reported on the Form 4 filed on June 13, 2023, erroneously included options held by the Reporting Person.

Remarks:

Test Form 4/A